Show simple item record

dc.contributor.authorFerreira, Daniel
dc.contributor.authorPerestelo-Pérez, Lilisbeth
dc.contributor.authorWestman, Eric
dc.contributor.authorWahlund, Lars-Olof
dc.contributor.authorSarría-Santamera, Antonio 
dc.contributor.authorSerrano-Aguilar, Pedro
dc.identifier.citationFront Aging Neurosci. 2014 Mar 24;6:47.es_ES
dc.description.abstractBACKGROUND: Current research criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF) biomarkers into the diagnostic algorithm. However, spreading their use to the clinical routine is still questionable. OBJECTIVE: To provide an updated, systematic and critical review on the diagnostic utility of the CSF core biomarkers for AD. DATA SOURCES: MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane Library, and CRD. ELIGIBILITY CRITERIA: (1a) Systematic reviews with meta-analysis; (1b) Primary studies published after the new revised diagnostic criteria; (2) Evaluation of the diagnostic performance of at least one CSF core biomarker. RESULTS: The diagnostic performance of CSF biomarkers is generally satisfactory. They are optimal for discriminating AD patients from healthy controls. Their combination may also be suitable for mild cognitive impairment (MCI) prognosis. However, CSF biomarkers fail to distinguish AD from other forms of dementia. LIMITATIONS: (1) Use of clinical diagnosis as standard instead of pathological postmortem confirmation; (2) variability of methodological aspects; (3) insufficiently long follow-up periods in MCI studies; and (4) lower diagnostic accuracy in primary care compared with memory clinics. CONCLUSION: Additional work needs to be done to validate the application of CSF core biomarkers as they are proposed in the new revised diagnostic criteria. The use of CSF core biomarkers in clinical routine is more likely if these limitations are overcome. Early diagnosis is going to be of utmost importance when effective pharmacological treatment will be available and the CSF core biomarkers can also be implemented in clinical trials for drug development.es_ES
dc.description.sponsorshipThe authors would like to thank the Spanish Working Group of the Report of Health Technology Assessment on the diagnostic accuracy of CSF biomarkers for AD (Evaluation Unit of the Canary Islands Health Service, Spanish Agencies and Units of Health Technology Assessment; HTA Reports: SESCS No 2012/08) for their support and helpful suggestions, as well as to the Fundación Canaria Dr Manuel Morales, the Swedish Brain Power and the Strategic Research Programme in Neuroscience at Karolinska Institutet (StratNeuro). The authors also thank Leticia Cuellar for her technical assistance with the search strategies and to Ma Carmen Bujalance for her assistance with the literature retrieval.es_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectamyloid beta-protein (42)es_ES
dc.subjectcerebrospinal fluid biomarkerses_ES
dc.subjectstate-of-the-art reviewes_ES
dc.subjecttau proteines_ES
dc.titleMeta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteriaes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.identifier.journalFrontiers in aging neurosciencees_ES
dc.repisalud.centroISCIII::Agencia de Evaluación de Tecnologías Sanitariases_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SESCS No 2012/08es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional